Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-06-20

Clinical Trial Update: PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating PEG-rhG-CSF to prevent chemotherapy-induced neutropenia in breast cancer patients has completed. Sponsor: CSPC Baike (Shandong) Bioph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PEG-rhG-CSF (pegylated recombinant human granulocyte colony-stimulating factor)

Snippet

Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Conditions: Breast Cancer | Phase 4 | Status: COMPLETED